Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 3/2023

22.03.2023 | Myokarditis | Zertifizierte Fortbildung

Umgang mit Therapienebenwirkungen

Kardiologische Langzeitfolgen nach Malignom-Behandlung*

verfasst von: Dr. med. Lars Michel, Prof. Dr. med. Tienush Rassaf

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Auszug

Die kardiovaskuläre Morbidität und Mortalität von Krebspatienten kann durch eine sinnvolle Risikoabschätzung, eine präzise Diagnostik sowie geeignete Maßnahmen zur Überwachung von Spätkomplikationen signifikant gesenkt werden. Dieser Beitrag gibt einen Überblick über die onkologischen Therapien sowie ihre möglichen kardiovaskulären Nebenwirkungen, um eine bestmögliche Behandlung der Patienten zu gewährleisten.
Literatur
1.
Zurück zum Zitat Michel L et al. Oncocardiology: new challenges, new opportunities. Herz. 2020;45(7):619-25 Michel L et al. Oncocardiology: new challenges, new opportunities. Herz. 2020;45(7):619-25
2.
Zurück zum Zitat Rassaf T et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109(10):1197-222 Rassaf T et al. Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. Clin Res Cardiol. 2020;109(10):1197-222
3.
Zurück zum Zitat Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-361 Lyon AR et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-361
4.
Zurück zum Zitat Zamorano JL et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801 Zamorano JL et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768-801
5.
Zurück zum Zitat Totzeck M et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163-75 Totzeck M et al. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol. 2019;280:163-75
6.
Zurück zum Zitat Lyon AR et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-60 Lyon AR et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945-60
7.
Zurück zum Zitat Michel L et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350-61 Michel L et al. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis. Eur J Heart Fail. 2020;22(2):350-61
8.
Zurück zum Zitat Cardinale D et al. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26 Cardinale D et al. Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020;7:26
9.
Zurück zum Zitat Totzeck M et al. Heart failure from cancer therapy: can we prevent it? ESC Heart Fail. 2019;6(4):856-62 Totzeck M et al. Heart failure from cancer therapy: can we prevent it? ESC Heart Fail. 2019;6(4):856-62
10.
Zurück zum Zitat Banfill K et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. J Thorac Oncol. 2021;16(2):216-27 Banfill K et al. Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions. J Thorac Oncol. 2021;16(2):216-27
11.
Zurück zum Zitat Bradley JA, Mendenhall NP. Novel Radiotherapy Techniques for Breast Cancer. Annu Rev Med. 2018;69:277-88 Bradley JA, Mendenhall NP. Novel Radiotherapy Techniques for Breast Cancer. Annu Rev Med. 2018;69:277-88
12.
Zurück zum Zitat Ellahham S et al. An overview of radiation-induced heart disease. Radiat Oncol J. 2022;40(2):89-102 Ellahham S et al. An overview of radiation-induced heart disease. Radiat Oncol J. 2022;40(2):89-102
13.
Zurück zum Zitat Mrotzek SM et al. Cardiovascular Damage Associated With Chest Irradiation. Front Cardiovasc Med. 2020;7:41 Mrotzek SM et al. Cardiovascular Damage Associated With Chest Irradiation. Front Cardiovasc Med. 2020;7:41
14.
Zurück zum Zitat Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021;10(18):e021686 Belzile-Dugas E, Eisenberg MJ. Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology. J Am Heart Assoc. 2021;10(18):e021686
15.
Zurück zum Zitat Taylor C et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641-9 Taylor C et al. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017;35(15):1641-9
16.
Zurück zum Zitat Haddy N et al. Cardiac Diseases Following Childhood Cancer Treatment. Circulation. 2016;133(1):31-8 Haddy N et al. Cardiac Diseases Following Childhood Cancer Treatment. Circulation. 2016;133(1):31-8
17.
Zurück zum Zitat Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37 Visseren FLJ et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-37
18.
Zurück zum Zitat Goel S et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail. 2019;7(9):795-804 Goel S et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC Heart Fail. 2019;7(9):795-804
19.
Zurück zum Zitat Dempsey N et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21-36 Dempsey N et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21-36
20.
Zurück zum Zitat Totzeck M et al. Cardiovascular Adverse Events in Patients ith Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc. 2017;6(8):e006278 Totzeck M et al. Cardiovascular Adverse Events in Patients ith Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc. 2017;6(8):e006278
21.
Zurück zum Zitat Dickerson T et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919-28 Dickerson T et al. Hypertension and incident cardiovascular events following ibrutinib initiation. Blood. 2019;134(22):1919-28
22.
Zurück zum Zitat Ganatra S et al. Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491-500 Ganatra S et al. Ibrutinib-Associated Atrial Fibrillation. JACC Clin Electrophysiol. 2018;4(12):1491-500
23.
Zurück zum Zitat Byrd JC et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021;39(31):3441-52 Byrd JC et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021;39(31):3441-52
24.
Zurück zum Zitat D'Souza M et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42(16):1621-31 D'Souza M et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J. 2021;42(16):1621-31
25.
Zurück zum Zitat Michel L et al. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420 Michel L et al. Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc. 2019;25:100420
26.
Zurück zum Zitat Lyon AR et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458 Lyon AR et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458
27.
Zurück zum Zitat Mahmood SS et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64 Mahmood SS et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755-64
28.
Zurück zum Zitat Awadalla M et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75(5):467-78 Awadalla M et al. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020;75(5):467-78
29.
Zurück zum Zitat Drobni ZD et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299-311 Drobni ZD et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299-311
30.
Zurück zum Zitat Ghosh AK et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2(1):97-109 Ghosh AK et al. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2(1):97-109
31.
Zurück zum Zitat Michel LT et al. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282-S4295 Michel LT et al. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282-S4295
32.
Zurück zum Zitat Michel L et al. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz. 2020;45(7):645-51 Michel L et al. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. Herz. 2020;45(7):645-51
Metadaten
Titel
Umgang mit Therapienebenwirkungen
Kardiologische Langzeitfolgen nach Malignom-Behandlung*
verfasst von
Dr. med. Lars Michel
Prof. Dr. med. Tienush Rassaf
Publikationsdatum
22.03.2023
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 3/2023
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-023-9854-8

Weitere Artikel der Ausgabe 3/2023

InFo Hämatologie + Onkologie 3/2023 Zur Ausgabe